Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.

"These three-year data show that raising the bar in atopic dermatitis treatment to long-term total skin clearance was an achievable treatment goal for at least half of EBGLYSS Week 16 responders, ...

The human monoclonal antibody known as tralokinumab-ldrm was tested and approved as a safe, effective treatment for pediatric patients with atopic dermatitis aged 12 to 17 years old. Originally ...

How do dermatologists diagnose atopic dermatitis? To diagnose atopic dermatitis, also called eczema, a board-certified dermatologist carefully examines your (or your child's) skin and asks questions. ...

Please provide your email address to receive an email when new articles are posted on . Pediatric patients treated with nemolizumab saw a statistically significant improvement in pruritus. Nemolizumab ...

Please provide your email address to receive an email when new articles are posted on . Ebglyss is a targeted interleukin-13 inhibitor approved for the treatment of moderate-to-severe atopic ...

(RTTNews) - Eli Lilly and Co. (LLY) announced that its Ebglyss monotherapy monthly injection demonstrated sustained and deep responses in patients with moderate-to-severe atopic dermatitis over three ...

European adult patients with atopic dermatitis most valued therapies that had rapid onset, oral administration, and were able to be paused—even at the expense of reduced efficacy. Patient preferences ...

MedPage Today brought together three expert leaders for a virtual roundtable discussion on atopic dermatitis: Moderator Peter Lio, MD, of Northwestern University Feinberg School of Medicine in Chicago ...

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 23 scientific posters at Maui Derm Hawaii 2026 (Jan. 25-29), showcasing a comprehensive body of evidence across ...